AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04401553
Drug: Second tier antibiotic (Vancomycin)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
Trial: NCT05821556
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT05821556
Drug: Gemcitabine 1000 mg
RxNorm normalized name: gemcitabine 1000 MG
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT05821556
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT01611480
Drug: Imiquimod (topical use)
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05821556
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT05625919
Drug: Sirolimus for Injection (Albumin Bound)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
Trial: NCT05222425
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal green tea
Trial: NCT00002385
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04707664
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
Trial: NCT05990790
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Trial: NCT05990790
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Trial: NCT05990790
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
Trial: NCT05689242
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
Trial: NCT04035902
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose is administered during surgery
Trial: NCT04035902
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric carboxymaltose is not administered
Trial: NCT05996432
Drug: 18F-fluoromisonidazole
RxNorm normalized name: (18F)-Fluoride
DrugBank: Misonidazole (DB11716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT03901001
Drug: sirolimus and oseltamivir
RxNorm normalized name: Sirolimus
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Trial: NCT03901001
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Trial: NCT05266651
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets for one month duration
Trial: NCT05216224
Drug: ATI-450
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, small molecule MK2 inhibitor
Trial: NCT05187429
Drug: Nivolumab 10 MG/ML [Opdivo]
RxNorm normalized name: nivolumab 10 MG/ML [Opdivo]
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
Trial: NCT05187429
Drug: Nivolumab 10 MG/ML [Opdivo]
RxNorm normalized name: nivolumab 10 MG/ML [Opdivo]
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
Trial: NCT05187429
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
Trial: NCT06118957
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
Trial: NCT00028327
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00028327
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00028327
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00028327
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00028327
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06122922
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Xenon Gas
Trial: NCT00031070
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00031070
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00031070
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04745975
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w
Trial: NCT04745975
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin 1.4 mg/m2, d1,8 q3w
Trial: NCT04745975
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25mg/m2 d1,8, q3w
Trial: NCT04745975
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2, d1,8, q3w
Trial: NCT05367843
Drug: PRIME-2-CoV_Beta
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection
Trial: NCT04787354
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130 mg/m2/day
Trial: NCT05223010
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for anaesthesia induction 3-8 MAC
Trial: NCT05431764
Drug: Camrelizumab, gemcitabin, cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.
Trial: NCT05512351
Drug: Tislelizumab plus Bevacizumab
RxNorm normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
Trial: NCT05362045
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04577001
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg orally daily for 6 months
Trial: NCT05157243
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
Trial: NCT05427084
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Canagliflozin tablet 300mg PO daily
Trial: NCT05155215
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 per day for 3 days (IV)
Trial: NCT05364619
Drug: Bismuth containing quadruple therapy
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth containing quadruple therapy for 14 days
Trial: NCT05909826
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70 mg/m2 IV days 1, 8 and 15, every 4 weeks
Trial: NCT05343117
Drug: Palbociclib based-therapy as initial endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
Trial: NCT05909826
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
Trial: NCT05343117
Drug: Palbociclib based-therapy after chemotherapy
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
Trial: NCT05221749
Drug: Nanosilver Fluoride (NSF)
RxNorm normalized name: Hydrogen fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimized synthesis of Nanosilver Fluoride
Trial: NCT05221749
Drug: Silver diamine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride
Trial: NCT04840888
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04840888
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04840888
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05222438
Drug: loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
Trial: NCT06083675
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as oral tablets.
Trial: NCT06083675
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as oral tablets.
Trial: NCT06083675
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as oral tablets.
Trial: NCT04956263
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
Trial: NCT04914598
Drug: ENDOSTAR，cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
Trial: NCT04914598
Drug: Placebo , cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo , cisplatin
Trial: NCT04939311
Drug: VB-201
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Trial: NCT06189885
Drug: Cefazolin with Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.
Trial: NCT06189885
Drug: Cefazolin with vancomycin
RxNorm normalized name: Cefazolin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
Trial: NCT04927039
Drug: 5ml of inhaled normal saline
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
Trial: NCT04927039
Drug: 20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
Trial: NCT05189509
Drug: TNK-Tissue Plasminogen Activator
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg TNK thrombolysis
Trial: NCT06433557
Drug: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
DrugBank: Lonapegsomatropin (DB16220)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
Trial: NCT04878315
Drug: Capoten
RxNorm normalized name: Capoten
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capoten will be administered per the treatment sequence
Trial: NCT04878315
Drug: Captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril will be administered per the treatment sequence
Trial: NCT05762536
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
Trial: NCT05762536
Drug: Docetaxel or cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel or cabazitaxel Q3W
Trial: NCT06306560
Drug: adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adebrelimab IV
Trial: NCT06306560
Drug: famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famitinib PO
Trial: NCT05078593
Drug: HLX26
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Trial: NCT05594602
Drug: EDP-235
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive EDP-235 on Days 1 and 14
Trial: NCT05594602
Drug: EDP-235
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive EDP-235 on Days 1 and 23
Trial: NCT05594602
Drug: EDP-235
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive EDP-235 on Days 1 and 8
Trial: NCT05594602
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive itraconazole QD Days 5-18